Location History:
- Rönninge, SE (2007)
- Lindome, SE (2005 - 2008)
Company Filing History:
Years Active: 2005-2008
Title: Jan-Erik Nyström: Innovator in Thrombin Inhibition
Introduction
Jan-Erik Nyström is a notable inventor based in Lindome, Sweden. He has made significant contributions to the field of medicinal chemistry, particularly in the development of thrombin inhibitors. With a total of 4 patents to his name, Nyström's work is pivotal in advancing treatments for conditions such as thrombosis.
Latest Patents
Nyström's latest patents include innovative compounds that serve as prodrugs of thrombin inhibitors. One of his notable inventions is a compound represented by the formula I, RO(O)C—CH—(R)Cgl-Aze-Pab-RI. This compound is particularly useful in the treatment of conditions requiring thrombin inhibition, such as thrombosis, and serves as an effective anticoagulant. Another significant patent involves amidino derivatives, which are competitive inhibitors of trypsin-like proteases, including thrombin. These compounds are also aimed at treating thrombosis and enhancing anticoagulant therapies.
Career Highlights
Nyström is currently associated with AstraZeneca AB, a leading global biopharmaceutical company. His work at AstraZeneca has allowed him to focus on developing innovative solutions in the field of thrombin inhibition. His research has the potential to impact the treatment landscape for patients suffering from thrombotic conditions.
Collaborations
Throughout his career, Nyström has collaborated with esteemed colleagues, including David Gustafsson and Thomas Antonsson. These collaborations have fostered a productive environment for innovation and have contributed to the success of his research endeavors.
Conclusion
Jan-Erik Nyström's contributions to the field of thrombin inhibitors exemplify the importance of innovation in medical science. His patents and ongoing work at AstraZeneca continue to pave the way for advancements in anticoagulant therapies.